Brain Scientific (BRSF) 10-Q 14 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 09, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	ALL SOFT GELS INC
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		10,000,000
Amendment Flag	false
Entity Central Index Key	1,662,382
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 60	$ 160
Accounts Receivable	57	0
Inventory	2,260	3,420
Total current assets	2,377	3,580
Total Assets	2,377	3,580
Current liabilities
Accounts payable	7,189	6,262
Due to related parties	70,358	42,863
Convertible notes payable	69,600	35,000
Total current liabilities	147,147	84,125
Commitments and contingencies
Stockholders’ equity (deficit)
Common stock, $0.001 par value, 50,000,000 shares authorized, 10,000,000 shares issued and outstanding as of September 30, 2017 and December 31, 2016.	10,000	10,000
Additional paid-in capital	4,303	238
Accumulated deficit	(159,073)	(90,783)
Total (deficiency in) stockholders’ equity	(144,770)	(80,545)
Total liabilities and stockholders’ equity	$ 2,377	$ 3,580

BALANCE SHEETS (Parentheticals)

BALANCE SHEETS (Parentheticals) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	10,000,000	10,000,000
Common stock, shares outstanding	10,000,000	10,000,000

STATEMENTS OF OPERATIONS (UNAUD

STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue	$ 272	$ 0	$ 7,022	$ 0
Cost of good sold	(20)	0	(1,160)	0
Gross Profit	252	0	5,862	0
Operating expenses:
General and administrative	27,908	24,282	70,087	69,373
Total operating expenses	27,908	24,282	70,087	69,373
Net Operating Loss	(27,656)	(24,282)	(64,225)	(69,373)
Other income (expense):
Interest expense	(1,403)	0	(4,065)	0
Total other expense	(1,403)	0	(4,065)	0
Loss before provision for income taxes	(29,059)	(24,282)	(68,290)	(69,373)
Provision for income taxes	0	0	0	0
Net loss	$ (29,059)	$ (24,282)	$ (68,290)	$ (69,373)
Net loss per share – basic & diluted (in Dollars per share)	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted average shares outstanding – basic & diluted (in Shares)	10,000,000	10,000,000	10,000,000	9,895,000

STATEMENTS OF CASH FLOWS (UNAUD

STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (68,290)	$ (69,373)
Adjustments to reconcile net loss to net cash used in operating activities:
Imputed interest	4,065	0
Changes in assets and liabilities:
Accounts receivable	(57)	0
Inventory	1,160	0
Accounts payable	927	30,360
Due to related parties	11,095	39,063
Net cash used in operating activities	(51,100)	50
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from officer loan	16,400	0
Proceeds from convertible notes payable	34,600	0
Net cash provided by financing activities	51,000	0
Net decrease in cash and cash equivalents	(100)	50
Cash and cash equivalents at beginning of period	160	50
Cash and cash equivalents at end of period	60	100
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	0	0
Income taxes paid	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Offset officer salary payable against subscription receivable	$ 0	$ 10,000

Note 1 - Nature of Business and

Note 1 - Nature of Business and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	Note 1 – Nature of Business and Significant Accounting Policies Reclassifications Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position, or cash flows. Nature of Business ALL SOFT GELS INC. (“the Company”) was incorporated in the state of Nevada on November 18, 2013 (“Inception”), to market a soft gel Kre-Alkalyn capsule. All Soft Gels, Inc. is a production stage company. All Soft Gels, Inc. has commenced its operations of having one product, a soft-gel capsule named All Soft Gels Kre-Alkalyn Liquid Gels, manufactured by an unaffiliated outside provider (Soft Gel Technologies, Inc. (SGTI) and the Company has one major order distributed and sold over 400 Bottles as of the date of this report. Basis of Presentation The financial statements have been prepared in accordance with United States generally accepted accounting principles and reflect all adjustments which, in the opinion of management, are necessary for a fair presentation. All such adjustments are of a normal recurring nature. The Company has adopted a fiscal year end of December 31st. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and equivalents include investments with initial maturities of three months or less. The Company maintains its cash balances at credit-worthy financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. Deposits with these banks may exceed the amount of insurance provided on such deposits; however, these deposits typically may be redeemed upon demand and, therefore, bear minimal risk. As of September 30, 2017 and December 31, 2016, the Company had no cash equivalents. Accounts Receivable Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Bad debts expense or write offs of receivables are determined on the basis of loss experience, known and inherent risks in the receivable portfolio and current economic conditions. During the periods ended September 30, 2017 and September 30, 2016, the Company wrote off accounts receivable totaling $0 and $0, respectively. There were no allowances for doubtful accounts recorded for the period ended September 30, 2017 or the year ended December 31, 2016. Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the establishment of deferred tax assets and liabilities for the temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided to the extent deferred tax assets may not be recoverable after consideration of the future reversal of deferred tax liabilities, tax planning strategies, and projected future taxable income. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments. The Company had no items that required fair value measurement on a recurring basis. Revenue recognition For revenue from product sales, the Company recognizes revenue using four basic criteria that must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgment regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, there were no outstanding potential common stock equivalents and therefore basic and diluted earnings per share result in the same figure. Stock-based compensation The Company adopted FASB guidance on stock based compensation upon inception at November 18, 2013. Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company did not issue any stock or options for services or compensation for the nine months ended September 30, 2017 and September 30, 2016. Our employee stock-based compensation awards are accounted for under the fair value method of accounting, as such, we record the related expense based on the more reliable measurement of the services provided, or the fair market value of the stock issued multiplied by the number of shares awarded. We account for our employee stock options under the fair value method of accounting using a Black-Scholes valuation model to measure stock option expense at the date of grant. We do not backdate, re-price, or grant stock-based awards retroactively. As of the date of this report, we have not issued any stock options. Recently Issued Accounting Pronouncements There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

Note 2 - Going Concern

Note 2 - Going Concern	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	Note 2 – Going Concern As shown in the accompanying financial statements, the Company has incurred recurring net losses from operations resulting in an accumulated deficit of $159,073, cash of $60, and a working capital deficit of ($144,770) as of September 30, 2017. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new ventures to increase revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful, therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 3 - Accounts receivable

Note 3 - Accounts receivable	9 Months Ended
	Sep. 30, 2017
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Note 3 – Accounts receivable Accounts receivable was $57 and $0 at September 30, 2017 and December 31, 2016, respectively. There was no allowance for uncollectible amounts on the Company’s balance sheet at September 30, 2017 as the balance is considered fully collectible.

Note 4 - Inventory

Note 4 - Inventory	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 – Inventory Inventory consists of soft-gel capsules produced by an independent third- party vendor. At September 30, 2017 and December 31, 2016, inventory consisted of the following: September 30, December 31, 2017 2016 Finished goods inventory $ 2,260 $ 3,420 Inventory is valued at the lower of cost or market, and is determined by the first-in, first-out method.

Note 5 - Convertible Notes Paya

Note 5 - Convertible Notes Payable	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 5 – Convertible Notes Payable In November 2016, the Company issued a convertible note payable to a third party investor for cash proceeds in the amount of $35,000 (the “November 2016 Convertible Note”. The November 2016 Convertible Note was originally due 90 days from the date of the note, but was further extended to December 1, 2017. At the discretion of the investor, this note is also convertible into common stock of the Company 90 days after issuance at a rate of $0.002 per share, or a total of 17,500,000 shares. Since the conversion price of the November 2017 Convertible Note was above the stock price of $0.001 established in recent transactions, there was no beneficial conversion feature or discount associated with this note. The Company calculated imputed interest at the rate of 8% per year on this note, and charged the amount of $706 and $2,093 to operations and credited additional paid-in capital during the three and nine months ended September 30, 2017. In January 2017, the Company issued a convertible note payable in the amount of $34,600 (the “January 2017 Convertible Note”). This note was originally due 90 days from the date of the note, but was further extended to At the discretion of the investor, this note is also convertible into common stock of the Company 90 days after issuance at a rate of $0.002 per share, or a total of 17,300,000 shares. Since the conversion price of the January 2017 Convertible Note was above the stock price of $0.001 established in recent transactions, there was no beneficial conversion feature associated with this note. The January 2017 Convertible Note was not funded until January 13, 2017, and therefore was recorded on the

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 6 – Related Party Transactions During the nine months ended September 30, 2017, the Company’s CEO, Gene Nelson, was paid the net amount of $30,000 as partial payment of accrued salary. At September 30, 2017, Mr. Nelson is owed the amount of $53,958 for accrued salary. During the nine months ended September 30, 2017, the Company’s CEO, Gene Nelson, advanced the company $16,400 to fund operations. These amounts bear interest at the rate of 3% per annum, and are due on demand.

Note 7 - Stockholder's Equity

Note 7 - Stockholder's Equity	9 Months Ended
	Sep. 30, 2017
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	Note 7 – Stockholders’ Equity The Company is authorized to issue 50,000,000 shares of $0.001 par value common stock. The Company has 10,000,000 common shares issued and outstanding as of September 30, 2017 and December 31, 2016. During the nine months ended September 30, 2017, the Company calculated imputed interest expense on its notes payable in the aggregate amount of $4,065; this amount was charged to additional paid-in capital.

Note 8 - Revenue

Note 8 - Revenue	9 Months Ended
	Sep. 30, 2017
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 8 – Revenue The Company has recorded revenue of $7,022 during the nine months ended September 30, 2017. These sales were to unaffiliated third parties for bottles of Creatinine Gels. The Company has sold approximately 407 units during the nine months ended September 30, 2017.

Note 9 - Subsequent Events

Note 9 - Subsequent Events	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 9 – Subsequent Events None.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Reclassification, Policy [Policy Text Block]	Reclassifications Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position, or cash flows.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The financial statements have been prepared in accordance with United States generally accepted accounting principles and reflect all adjustments which, in the opinion of management, are necessary for a fair presentation. All such adjustments are of a normal recurring nature. The Company has adopted a fiscal year end of December 31st.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and equivalents include investments with initial maturities of three months or less. The Company maintains its cash balances at credit-worthy financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. Deposits with these banks may exceed the amount of insurance provided on such deposits; however, these deposits typically may be redeemed upon demand and, therefore, bear minimal risk. As of September 30, 2017 and December 31, 2016, the Company had no cash equivalents.
Receivables, Policy [Policy Text Block]	Accounts Receivable Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Bad debts expense or write offs of receivables are determined on the basis of loss experience, known and inherent risks in the receivable portfolio and current economic conditions. During the periods ended September 30, 2017 and September 30, 2016, the Company wrote off accounts receivable totaling $0 and $0, respectively. There were no allowances for doubtful accounts recorded for the period ended September 30, 2017 or the year ended December 31, 2016.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the establishment of deferred tax assets and liabilities for the temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided to the extent deferred tax assets may not be recoverable after consideration of the future reversal of deferred tax liabilities, tax planning strategies, and projected future taxable income.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments. The Company had no items that required fair value measurement on a recurring basis.
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition For revenue from product sales, the Company recognizes revenue using four basic criteria that must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgment regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, there were no outstanding potential common stock equivalents and therefore basic and diluted earnings per share result in the same figure.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-based compensation The Company adopted FASB guidance on stock based compensation upon inception at November 18, 2013. Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company did not issue any stock or options for services or compensation for the nine months ended September 30, 2017 and September 30, 2016. Our employee stock-based compensation awards are accounted for under the fair value method of accounting, as such, we record the related expense based on the more reliable measurement of the services provided, or the fair market value of the stock issued multiplied by the number of shares awarded. We account for our employee stock options under the fair value method of accounting using a Black-Scholes valuation model to measure stock option expense at the date of grant. We do not backdate, re-price, or grant stock-based awards retroactively. As of the date of this report, we have not issued any stock options.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of soft-gel capsules produced by an independent third- party vendor. At September 30, 2017 and December 31, 2016, inventory consisted of the following: September 30, December 31, 2017 2016 Finished goods inventory $ 2,260 $ 3,420

Note 1 - Nature of Business a17

Note 1 - Nature of Business and Significant Accounting Policies (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Accounting Policies [Abstract]
Allowance for Doubtful Accounts Receivable, Write-offs	$ 0	$ 0

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Retained Earnings (Accumulated Deficit)	$ (159,073)	$ (90,783)
Cash	60
Working Capital (Deficit)	$ (144,770)

Note 3 - Accounts receivable (D

Note 3 - Accounts receivable (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Receivables [Abstract]
Accounts Receivable, Net, Current	$ 57	$ 0

Note 4 - Inventory (Details) -

Note 4 - Inventory (Details) - Schedule of Inventory, Current - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Schedule of Inventory, Current [Abstract]
Finished goods inventory	$ 2,260	$ 3,420

Note 5 - Convertible Notes Pa21

Note 5 - Convertible Notes Payable (Details)	1 Months Ended		3 Months Ended	9 Months Ended
	Dec. 31, 2016USD ($)$ / shares	Nov. 30, 2016USD ($)$ / shares	Sep. 30, 2017USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)
Note 5 - Convertible Notes Payable (Details) [Line Items]
Imputed Interest				$ 4,065	$ 0
Convertible Notes Payable [Member] | Convertible Notes #1 [Member]
Note 5 - Convertible Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount		$ 35,000
Debt Instrument, Term		90 days
Debt Instrument, Convertible, Terms of Conversion Feature	this note is also convertible into common stock of the Company 90 days after issuance at a rate of $0.002 per share	this note is also convertible into common stock of the Company 90 days after issuance at a rate of $0.002 per share
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares		$ 0.002
Debt Instrument, Convertible, Number of Equity Instruments		17,500,000
Debt Instrument, Imputed Interest Rate		8.00%
Imputed Interest			$ 706	2,093
Convertible Notes Payable [Member] | Convertible Notes #2 [Member]
Note 5 - Convertible Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount	$ 34,600
Debt Instrument, Term	90 days
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares	$ 0.002
Debt Instrument, Convertible, Number of Equity Instruments	17,300,000
Debt Instrument, Imputed Interest Rate	8.00%
Imputed Interest			$ 697	$ 1,972

Note 6 - Related Party Transa22

Note 6 - Related Party Transactions (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Note 6 - Related Party Transactions (Details) [Line Items]
Due to Related Parties, Current	$ 70,358		$ 42,863
Proceeds from Related Party Debt	16,400	$ 0
Chief Executive Officer [Member]
Note 6 - Related Party Transactions (Details) [Line Items]
Repayments of Related Party Debt	30,000
Due to Related Parties, Current	53,958
Proceeds from Related Party Debt	$ 16,400
Debt Instrument, Imputed Interest Rate	3.00%

Note 7 - Stockholder's Equity (

Note 7 - Stockholder's Equity (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Disclosure Text Block Supplement [Abstract]
Common Stock, Shares Authorized	50,000,000		50,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.001		$ 0.001
Common Stock, Shares, Issued	10,000,000		10,000,000
Common Stock, Shares, Outstanding	10,000,000		10,000,000
Imputed Interest (in Dollars)	$ 4,065	$ 0

Note 8 - Revenue (Details)

Note 8 - Revenue (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)
Revenue from Contract with Customer [Abstract]
Revenues	$ 272	$ 0	$ 7,022	$ 0
Number of Bottles Sold			407